Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma
Blood Podcast
00:00
The Impact of 1P32 Deletion in Newly Diagnosed Multiple Myeloma
Of 2,551 studied patients, 11% were found to have deletion 1P32. The overall survival of these patients was significantly inferior compared to patients who did not harbor 1P32 deletion. After adjusting for age and treatment, the risk of disease progression was 1.3 times higher in patients harboring 1P32 deletions.
Transcript
Play full episode
